Biogen Inc.

Location

Massachusetts

Founded

1978-02-28

Website

https://www.biogen.com

Risk Signals

6610 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Strategic Partnerships (8) Business Growth Initiatives (1) Business Launches (1) Corporate Relocations (1) Funding Announcements (1) Acquisition Announcements (1) New Product Release (1) Real Estate Projects (1) Startup Launches (1) Joint Ventures (1)

Recent Articles about Biogen Inc.

Live alerts from global media, monitored by Business Radar

2025-04-22 (centralnews.co.za)

Mamelodi Sundowns Secure Premium Wellness Partnership With Biogen to Elevate Player Nutrition and Recovery | South Africa

Mamelodi Sundowns have secured a groundbreaking partnership with Biogen South Africa, a premium wellness brand, to become the club's official supplements

2025-04-14 (statnews.com)

A research transformation: An open model for innovation at Biogen |

Biogen isn't shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development

2025-04-14 (centerforbiosimilars.com)

Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.

2025-04-01 (managedhealthcareexecutive.com)

Organon Expands Biosimilar Portfolio With Tofidence Acquisition

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the U.S. market, launching in May 2024.